Key Highlights: Implications: Zydus’ smart-pen assault smashes generic pricing barriers, handing endocrinologists flexible dosing that trumps competitor pens while exploding Tier-2 a...
Key Highlights: Implications: Anyra smashes Eylea pricing barriers, flooding retina clinics with budget-friendly therapy that keeps patients compliant for years. Zydus seizes op...
Key Highlights: Implications: PEPAIR smashes cost barriers to OPEP therapy, handing pulmonologists a game-changing tool that slots perfectly alongside Zydus inhalers and Deriphyllin....
Key Highlights: Implications: Tishtha detonates pricing bombs on Roche’s Tecentriq and MSD’s Opdivo, handing cash-strapped hospitals a lifeline while exploding p...
